21.20.Z - Manufacture of medicines and other pharmaceutical products
10.89.Z - Manufacture of other food products not elsewhere classified
20.14.Z - Manufacture of other organic basic chemicals
20.42.Z - Manufacture of perfumes and toilet preparations
21.10.Z - Manufacture of basic pharmaceutical substances
46.45.Z - Wholesale of perfume and cosmetics
46.46.Z - Wholesale of pharmaceutical goods
68.20.Z - Rental and operating of own or leased real estate
72.19.Z - Other research and experimental development on natural sciences and engineering
82.92.Z - Packaging activities
2018 | 2019 | 2020 | ||
---|---|---|---|---|
M PLN | M PLN | M PLN | % | |
Net sales | 48,7 | 39,6 | 39 | -1,4 |
Liabilities and provisions | 13,3 | 18,7 | 17,9 | -4,3 |
Equity | 27,5 | 22,5 | 22,7 | 0,9 |
Total assets | 40,8 | 41,2 | 40,6 | -1,4 |
Cash and cash equivalents | 0,3 | 0 | 0,7 | 1664,7 |
Depreciation | 1,4 | 1,2 | 0,9 | -26 |
Gross profit / loss | 0,3 | -4,5 | 0,2 | 103,5 |
EBITDA | 2,2 | -2,8 | 1,5 | 153,6 |
Net profit / loss | 0,3 | -4,5 | 0,5 | 110,8 |
Operating profit (EBIT) | 0,8 | -4 | 0,6 | 115,2 |
Current assets | 15,5 | 16,8 | 18,1 | 8 |
% | % | % | p.p. | |
Return on equity (ROE) | 1,2 | -20 | 2,1 | 22,1 |
Return on sales (ROS) | 0,7 | -11,3 | 1,2 | 12,5 |
Equity ratio | 67,5 | 54,6 | 55,9 | 1,3 |
EBITDA margin | 4,6 | -7 | 3,8 | 10,8 |
Gross profit margin | 0,6 | -11,3 | 0,4 | 11,7 |
Days | Days | Days | Days | |
Current liabilities turnover ratio | 62 | 136 | 110 | -26 |
Current ratio | 1,6 | 1 | 1,3 | 0,3 |
Net debt to EBITDA | 2,3 | -1,7 | 3,8 | 5,5 |
Opinions regarding services, products, and company activities are not verified. This means that ING Services for Business S.A., as the provider of the Aleo platform, does not ensure that the published opinions come from consumers who have used the product or availed of the company's services. However, we do strive to ensure that opinions do not violate universally applicable laws.